Pre-clinical studies have demonstrated mixed findings, including potential protective effects of GLP-1 RAs in the context of diabetic retinopathy, with GLP-1 receptors found in the RPE serving a neuroprotective role in conditions of high glucose
While they both belong to the GLP-1 class, they work in slightly different ways
inflammation, granulomatous, focus/foci of mononuclear cells
Promotes weight-loss
Considering that this group of medications significantly reduces lean muscle mass, which may be particularly risky in elderly patients, those who do not lose weight or rather gain weight while using GLP1 RAs, may not be suitable to continue using these medications [20]
Expression could be achieved using adenoassociated virus vectors/marrow stromal cells (MSCs) or nonviral intravenous agents involving rat transferrin receptor monoclonal antibodies (TfRmAb) targeted to PE glycated immunoliposomes